Amrutanjan Health Care Ltd
Amrutanjan Health Care Ltd Q3 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY25 Net Sales: Rs. Quarterly EBITDA/Operating Margin: - The presentation does not explicitly state EBITDA figures for the quarter. - Operating margin expansion is noted as 69 basis points improvement due to improved operational efficiencies (Page 22 Management Commentary). - Profit After Tax (PAT) Q3 FY25: - PAT: Rs.
From Amrutanjan Health Care Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr)
- Q3 FY25 Net Sales - OTC: Rs. 117.86 Cr, up 5.43% YoY (Q3 FY24: Rs. 111.79 Cr)
- Q3 FY25 Net Sales - Comfy: Rs. 29.93 Cr, up slightly from Rs. 29.36 Cr YoY
- Q3 FY25 Net Sales - Beverages: Rs. 4.42 Cr, down from Rs. 5.18 Cr YoY
- Q3 FY25 Net Sales - Electro Plus: Rs. 4.31 Cr, down from Rs. 4.62 Cr YoY
- YTD Dec’24 Net Sales: Rs. 316.40 Cr, up 7.56% YoY (YTD Dec’23: Rs. 294.17 Cr)
- YTD Dec’24 OTC Division Sales: Rs. 296.75 Cr, up 9.09% YoY (YTD Dec’23: Rs. 272.02 Cr)
- Pain balm consumption volume growth in Dec quarter: 9.1% (IQVIA), highest in 20 quarters (excluding COVID)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY25 investor presen
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key investor presentation takeaways from NGL Fine Chem Ltd's Q
- Shree Ganesh Remedies Ltd (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation — and how it ra
- Themis Medicare Ltd (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY25 investor presentation — and how i
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q3 FY25 results?
Q3 FY25 Net Sales: Rs. Quarterly EBITDA/Operating Margin: - The presentation does not explicitly state EBITDA figures for the quarter. - Operating margin expansion is noted as 69 basis points improvement due to improved operational efficiencies (Page 22 Management Commentary). - Profit After Tax (PAT) Q3 FY25: - PAT: Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
The investor presentation does not mention any capex, capacity expansion, new plant, or project details, including amounts, status, or timelines.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.